BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• Business

  Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China

  Roivant Sciences and ArQule today announced the initiation of a collaboration to pursue the development of derazantinib, a pan-FGFR (fibroblast growth factor receptor) inhibitor, in Greater China.

  February 7, 2018

   · 

  8 min read
• Time to Elevate Protection in Haemophilia Care: New Data From Sobi

  Sobi will present new evidence at the upcoming 11th Annual Congress of the European Association for Haemophilia and Allied Disorders, in Madrid, Spain, 7-9 February 2018.

  February 7, 2018

   · 

  9 min read
• Appili Therapeutics Raises an Additional $4.3 Million in Oversubscribed Financing to Advance its Anti-infective Pipeline

  Appili Therapeutics today it raised an additional $4,339,000 in an oversubscribed private placement financing, bringing the total equity raised since its seed round in March 2016 to $11,816,000.

  February 7, 2018

   · 

  3 min read
• Pharm Country

  Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEX

  Eagle today announced that the Company has been issued a new patent related to its RYANODEX product (dantrolene sodium for injectable suspension) by the United States Patent and Trademark Office (USPTO).

  February 7, 2018

   · 

  4 min read
• Biotech Beach

  Nasdaq Grants BIOLASE 180-Day Extension to Meet Minimum Bid Price Requirement

  As previously disclosed, BIOLASE received notice from Nasdaq on August 9, 2017, that it was not in compliance with the Bid Price Requirements for its common stock.

  February 7, 2018

   · 

  3 min read
• 

  Drug Development

  Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop

  Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo.

  February 7, 2018

   · 

  6 min read
• Lone Star Bio

  US Bioservices Announces Record Breaking Year for New Business Wins in Rare & Orphan, Oncology and Specialty Infusion

  US Bioservices announced that 2017 was a record breaking year for new business wins in three strategic areas – oncology, rare and orphan and specialty infusion.

  February 7, 2018

   · 

  4 min read
• Biotech Beach

  Innovus Pharma Announces the Publication of a Successful Clinical Trial in Overactive Bladder and Urine Incontinence Patients for its UriVarx Product

  Innovus Pharma announced that the human clinical trial for the patented formulation in its product UriVarx product for bladder health was published in the peer reviewed journal, BMC Complementary and Alternative Medicine (Schoendorfer et al. BMC Complementary and Alternative Medicine (2018) 18:42).

  February 7, 2018

   · 

  4 min read
• 

  Drug Development

  On a Roll: FDA Calls Sage’s Depression Drug a Breakthrough

  This is the second Breakthrough Therapy designation granted to Sage since 2016.

  February 7, 2018

   · 

  6 min read
• Policy

  Verastem Submits NDA to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma

  In addition, duvelisib received orphan drug designation in the United States and the European Union for patients with CLL, SLL and FL.

  February 7, 2018

   · 

  8 min read